Abstract
Background Biguanide (BG) is the most-prescribed oral glucose-lowering medication worldwide and has potential for further therapeutic applications. The Coronavirus disease 2019 (COVID-19) pandemic is a global public health emergency. Nevertheless, there are still no established low-cost treatments against COVID-19, of which the morbidity and mortality rates varing from country to country. Therefore, a nationwide study of the COVID-19 affected population is essential to explore therapeutic effect of BG against COVID-19.
Methods From the inpatient databases in Japan, covering the period from September 2021 to March 2023, which encompasses the era following the development of COVID-19 vaccines, we extracted data of 168,370 COVID-19 patients aged 20 to under 80 years who were suffered from diabetes mellitus treated with oral antidiabetic agents. The primary outcome was 100-day in-hospital mortality, and secondary outcome was the incidence of acute kidney injury (AKI) during hospitalization. We compared outcomes in patients who received BG with those in patients who did not, using a logistic regression analysis and Cox proportional hazards under both propensity score-unmatched and matched cohorts.
Results The incidence of in-hospital death was significantly lower in the BG group (1.18 %) compared to the non-BG group (2.41%) (p < 0.001). Similarly, the incidence of AKI during hospitalization was significantly lower in the BG group (0.66 %) compared to the non-BG group (1.12%) (p < 0.001). Kaplan-Meier analysis from the propensity-score matched cohort showed a significantly better survival rate in the BG group (adjusted HR, 0.580; 95% CI 0.510-0.658; p < 0.001).
Conclusion In COVID-19 patients, the use of oral biguanide use may be associated with a reduced in-hospital mortality and risk of AKI.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Grant-in-Aid for Research Activity Start-up (23K19610) to H. Kikuchi, Grant-in-Aid for Early-Career Scientists (24K19143) to H. Kikuchi, Japan Agency for Medical Research and Development (AMED), Grant Number 24ek0310023h0001 to H. Kikuchi, and the Uehara Memorial Foundation to H. Kikuchi.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Board of Tokyo Medical and Dental University (no. M2000-788).Informed consent was waived because of the anonymous nature of the data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
